186 related articles for article (PubMed ID: 30478273)
1. Enhanced anti-metastatic bioactivity of an IGF-TRAP re-engineered to improve physicochemical properties.
Vaniotis G; Moffett S; Sulea T; Wang N; Elahi SM; Lessard E; Baardsnes J; Perrino S; Durocher Y; Frystyk J; Massie B; Brodt P
Sci Rep; 2018 Nov; 8(1):17361. PubMed ID: 30478273
[TBL] [Abstract][Full Text] [Related]
2. Targeting the IGF-Axis for Cancer Therapy: Development and Validation of an IGF-Trap as a Potential Drug.
Chen YM; Qi S; Perrino S; Hashimoto M; Brodt P
Cells; 2020 Apr; 9(5):. PubMed ID: 32365498
[TBL] [Abstract][Full Text] [Related]
3. The IGF-Trap: Novel Inhibitor of Carcinoma Growth and Metastasis.
Wang N; Rayes RF; Elahi SM; Lu Y; Hancock MA; Massie B; Rowe GE; Aomari H; Hossain S; Durocher Y; Pinard M; Tabariès S; Siegel PM; Brodt P
Mol Cancer Ther; 2015 Apr; 14(4):982-93. PubMed ID: 25673819
[TBL] [Abstract][Full Text] [Related]
4. An investigation of the ligand binding properties and negative cooperativity of soluble insulin-like growth factor receptors.
Surinya KH; Forbes BE; Occhiodoro F; Booker GW; Francis GL; Siddle K; Wallace JC; Cosgrove LJ
J Biol Chem; 2008 Feb; 283(9):5355-63. PubMed ID: 18056713
[TBL] [Abstract][Full Text] [Related]
5. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
Sachdev D; Li SL; Hartell JS; Fujita-Yamaguchi Y; Miller JS; Yee D
Cancer Res; 2003 Feb; 63(3):627-35. PubMed ID: 12566306
[TBL] [Abstract][Full Text] [Related]
6. A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.
Schanzer JM; Wartha K; Croasdale R; Moser S; Künkele KP; Ries C; Scheuer W; Duerr H; Pompiati S; Pollman J; Stracke J; Lau W; Ries S; Brinkmann U; Klein C; Umana P
J Biol Chem; 2014 Jul; 289(27):18693-706. PubMed ID: 24841203
[TBL] [Abstract][Full Text] [Related]
7. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
[TBL] [Abstract][Full Text] [Related]
8. Insulin-like growth factor-II expression in carcinoma in colon cell lines: implications for autocrine actions.
Guo YS; Jin GF; Townsend CM; Zhang T; Sheng HM; Beauchamp RD; Thompson JC
J Am Coll Surg; 1995 Aug; 181(2):145-54. PubMed ID: 7627387
[TBL] [Abstract][Full Text] [Related]
9. Functional evaluation of novel soluble insulin-like growth factor (IGF)-II-specific ligand traps based on modified domain 11 of the human IGF2 receptor.
Prince SN; Foulstone EJ; Zaccheo OJ; Williams C; Hassan AB
Mol Cancer Ther; 2007 Feb; 6(2):607-17. PubMed ID: 17308058
[TBL] [Abstract][Full Text] [Related]
10. Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition.
Croasdale R; Wartha K; Schanzer JM; Kuenkele KP; Ries C; Mayer K; Gassner C; Wagner M; Dimoudis N; Herter S; Jaeger C; Ferrara C; Hoffmann E; Kling L; Lau W; Staack RF; Heinrich J; Scheuer W; Stracke J; Gerdes C; Brinkmann U; Umana P; Klein C
Arch Biochem Biophys; 2012 Oct; 526(2):206-18. PubMed ID: 22464987
[TBL] [Abstract][Full Text] [Related]
11. A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity.
Dong J; Sereno A; Aivazian D; Langley E; Miller BR; Snyder WB; Chan E; Cantele M; Morena R; Joseph IB; Boccia A; Virata C; Gamez J; Yco G; Favis M; Wu X; Graff CP; Wang Q; Rohde E; Rennard R; Berquist L; Huang F; Zhang Y; Gao SX; Ho SN; Demarest SJ; Reff ME; Hariharan K; Glaser SM
MAbs; 2011; 3(3):273-88. PubMed ID: 21393993
[TBL] [Abstract][Full Text] [Related]
12. Bioactive insulin-like growth factors as a possible molecular target for non-islet cell tumor hypoglycemia.
Setoyama T; Miyamoto S; Horimatsu T; Funakoshi T; Nikaido M; Kodama Y; Minamiguchi S; Yamabata T; Muto M; Chiba T
Cancer Biol Ther; 2014; 15(12):1588-92. PubMed ID: 25535894
[TBL] [Abstract][Full Text] [Related]
13. AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells.
Beltran PJ; Mitchell P; Chung YA; Cajulis E; Lu J; Belmontes B; Ho J; Tsai MM; Zhu M; Vonderfecht S; Baserga R; Kendall R; Radinsky R; Calzone FJ
Mol Cancer Ther; 2009 May; 8(5):1095-105. PubMed ID: 19366899
[TBL] [Abstract][Full Text] [Related]
14. Luteolin decreases IGF-II production and downregulates insulin-like growth factor-I receptor signaling in HT-29 human colon cancer cells.
Lim DY; Cho HJ; Kim J; Nho CW; Lee KW; Park JH
BMC Gastroenterol; 2012 Jan; 12():9. PubMed ID: 22269172
[TBL] [Abstract][Full Text] [Related]
15. A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo.
Ji QS; Mulvihill MJ; Rosenfeld-Franklin M; Cooke A; Feng L; Mak G; O'Connor M; Yao Y; Pirritt C; Buck E; Eyzaguirre A; Arnold LD; Gibson NW; Pachter JA
Mol Cancer Ther; 2007 Aug; 6(8):2158-67. PubMed ID: 17671083
[TBL] [Abstract][Full Text] [Related]
16. Role for membrane and secreted insulin-like growth factor-binding protein-2 in the regulation of insulin-like growth factor action in lung tumors.
Reeve JG; Morgan J; Schwander J; Bleehen NM
Cancer Res; 1993 Oct; 53(19):4680-5. PubMed ID: 7691401
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic and antineoplastic activity of BI 836845, a fully human IGF ligand-neutralizing antibody, and mechanistic rationale for combination with rapamycin.
Friedbichler K; Hofmann MH; Kroez M; Ostermann E; Lamche HR; Koessl C; Borges E; Pollak MN; Adolf G; Adam PJ
Mol Cancer Ther; 2014 Feb; 13(2):399-409. PubMed ID: 24296829
[TBL] [Abstract][Full Text] [Related]
18. R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axis.
Huang HJ; Angelo LS; Rodon J; Sun M; Kuenkele KP; Parsons HA; Trent JC; Kurzrock R
PLoS One; 2011; 6(10):e26060. PubMed ID: 22022506
[TBL] [Abstract][Full Text] [Related]
19. Fluorescent-Antibody Targeting of Insulin-Like Growth Factor-1 Receptor Visualizes Metastatic Human Colon Cancer in Orthotopic Mouse Models.
Park JY; Murakami T; Lee JY; Zhang Y; Hoffman RM; Bouvet M
PLoS One; 2016; 11(1):e0146504. PubMed ID: 26731105
[TBL] [Abstract][Full Text] [Related]
20. Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function.
Feng Y; Zhu Z; Xiao X; Choudhry V; Barrett JC; Dimitrov DS
Mol Cancer Ther; 2006 Jan; 5(1):114-20. PubMed ID: 16432169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
